Disease Group


Disease Group Profile

Our group focuses on developing novel early phase trials for all lymphoma subtypes, and in partnering with industry on practice changing phase 3 clinical trials. Our members include junior and senior faculty from both academic and community institutions and collaboration within the group is encouraged. We currently have trials active or in development in Hodgkin lymphoma, Mantle Cell lymphoma, and DLBCL. We hope to expand in the areas of indolent lymphomas and T cell lymphomas.

Disease Group Leaders

Yucai Wang, M.D.

Mayo Clinic Rochester, MN

Yucai Wang, MD, PhD is a hematologist specializing in lymphoma, CLL, and cell therapy at Mayo Clinic, Rochester, MN. His research interest includes novel therapies for lymphoma and CLL and translational research in genetics and immunology.

Catherine Diefenbach, M.D.


Catherine Diefenbach, M.D. is an Associate Professor in the Division of Hematology and Medical Oncology in the NYU Perlmutter Cancer Center (PCC) at NYU Langone Health, the Clinical Director of Lymphoma, and the Translational Director of Hematology, and the Co-Chair of the Lymphoma Committee of the ACCRU network. Her research focuses on the relationship between systemic immunity, and tumor microenvironment and spans from investigator initiated clinical trials correlative science, to non-therapeutic investigations in collaboration with basic scientists.

Disease Group Clinical Trials